Ind-Swift Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+14.2%−56.1%+6.1%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+332.6%−107.6%+10.9%
+133.0%−121.8%+16.9%
−83.5%−40.6%+785.5%
−86.7%−47.7%+783.9%
+16.3%+23.5%−36.1%
+18.0%+25.9%+36.6%
−148.0%+85.9%−192.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDSWFTLAB₹409.80

Ind-Swift Laboratories Limited

· Pharma & Health
₹ CrorePeersSMSPHARMASOLARADCALHIKALUNICHEMLABGUFICBIOPANACEABIORPGLIFEMcap ₹3,559 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+6.1-56.1+14.2—
EBITDA Growth—+10.9-107.6+332.6—
EBIT Growth—+16.9-121.8+133.0—
Net Income Growth—+785.5-40.6-83.5—
EPS Growth—+783.9-47.7-86.7—
Total Assets Growth—-36.1+23.5+16.3—
Total Equity Growth—+36.6+25.9+18.0—
Cash from Operations Growth—-192.9+85.9-148.0—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.